Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 6, 2014

View Archived Issues

Scynexis enters into global agreement with Waterstone Pharmaceutical for SCY-635

New York Blood Center and Blood Center of Wisconsin join NAITgam development consortium

Hanmi and partner Kinex report preliminary data from phase I study of Oratecan

Sunovion and ex scientia collaborate to discover novel medicines for psychiatric disorders

Novo Nordisk reports highlights of third quarter 2014

Researchers presented genetic biomarkers of cardiac dysfunction

Integra LifeSciences plans to spin off spinal surgery business

Transition Therapeutics reports data from phase II study of ELND-005 in bipolar disorder

Karus Therapeutics presents novel highly selective HDAC6 inhibitors

Phase III data presented on new levonorgestrel intrauterine contraceptive system

New URAT1 inhibitors patented by Pfizer

Singapore A*STAR reports novel Wnt pathway modulators

Esteve presents new sigma1 receptor ligands

Roche and Siena Biotech develop new BACE1 inhibitors

Sage Therapeutics presents new neuroactive steroids

University of Illinois patents new vWF secretion inhibitors

Vertex applies for U.S. and E.U. approvals of lumacaftor/ivacaftor

CYD tetravalent dengue vaccine found efficacious in phase III studies in children in Latin America

FDA approves ramucirumab in combination with paclitaxel for advanced gastric cancer

Regulatory submissions filed for mepolizumab for severe eosinophilic asthma in the U.S. and E.U.

New clinical data presented on nivolumab in the treatment of renal cell carcinoma

Advaxis submits IND application for ADXS31-142 for metastatic prostate cancer

FDA grants orphan drug designation to MM-141 for the treatment of pancreatic cancer

Isis Pharmaceuticals earns milestone payment from GSK for ISIS-GSK5-Rx

FDA approves Olysio in combination with sofosbuvir for genotype 1 chronic HCV

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 28, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...
Grace Therapeutics hits CRL setback with GTx-104 despite positive trial
BioWorld
Grace Therapeutics Inc.’s hopes of becoming the first company in decades to update the standard of care in aneurysmal subarachnoid hemorrhage were delayed after...